Video

News

AAO 2024: Applying large language models in revenue cycle management

Key Takeaways

  • Large language models are being utilized to improve revenue cycle management, particularly in prior authorizations, enhancing efficiency in medical transactions.
  • A pilot at Johns Hopkins Medicine showed a 25% productivity increase, with LLMs recommending necessary documents in over 70% of cases.
SHOW MORE

In a presentation at the American Academy of Ophthalmology’s annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).

This transcript has been lightly edited for clarity.

T.Y. Alvin Liu, MD: Hello everyone. My name is Alvin Lu. I'm a retina specialist at the Wilmer Eye Institute, and I'm also on the AI Operations team at Johns Hopkins Medicine, and this newly established team with a purview over all things AI related in the clinical, operational and imaging domains. And later today, I have the honor of giving a talk that focuses on using large language models (LLMs) for revenue cycle management.

As you know, the vast majority of medical transactions in the US are carried through medical insurance, and therefore revenue cycle and management is extremely important. That's exactly how health systems and providers get paid by insurance payers. RCM management, in itself, is a big business. It's estimated that each year, about $150 billion are involved in RCM management. However, this process is also very tedious, with a lot of pain points and inflections. Therefore, one of the most promising use cases of large language models to use LLMs for revenue cycle management such as prior authorization.

We at Johns Hopkins Medicine recently performed a pilot for this exact purpose, and so far, we have been able to demonstrate that we improved productivity by about 25% and in over 70% of all the prior authorizations, all the required documents to be uploaded were, in fact, recommended by this LLM. This is certainly a very exciting area of development for healthcare AI overall, and certainly for ophthalmology, because, as you know, obtaining the correct prior authorizations is important for ophthalmology, especially in the context of intravitreal injections in retina.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.